Personalis reports FY2024 revenue ~$84.6M (+15% YoY), above guidance; cash ~$185M

Personalis, Inc.

2024-FY EPS reported -$1.37 revenue$84,614,000

Full year 2024 revenue of ~$84.6M, up 15% from $73.5M in 2023, above guidance range of $83-84M.
Pharma/enterprise/other revenue grew 20% to ~$77.2M despite Natera revenue declining 20% to ~$25.4M.
Q4 revenue of ~$16.8M (down 15% YoY); delivered 1,441 molecular tests, up 52% from Q3.
Cash, cash equivalents, and short-term investments of ~$185.0M, including $50M strategic investment from Merck; path to cash flow break-even.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.